Get the Weekly Intelligence Brief — top committee picks every Sunday.
TMDX · NASDAQ · STOCK

TransMedics Group (TMDX) Stock Analysis

Healthcare Updated September 17, 2026
$87.44
52W $60.10 – $156.00
57/100
$3.04B
19.9
1.88
AI Committee Verdict
Watch
57/100
Conviction: Contested · 50% agreement · 6 analysts
+37.1%
-22.6%
1.64:1
Contested

Is TMDX Bullish or Bearish?

Mixed. Innellis AI committee rates TransMedics Group, Inc. (TMDX) Watch with a composite score of 57/100 , based on 6 analysts with 50% agreement. Last updated September 17, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +3.27 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -16.73 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 25.8% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 17.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 33.0% shows genuine earnings power backing the valuation — Value
  • Revenue growing 25.8% YoY -- genuine top-line momentum — Growth
  • EPS growing 105.5% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • News sentiment is positive (+0.33 across 9 articles, 14d) — News
Bear Case
  • Price-to-book of 8.8x prices in significant intangible value — Value
  • 2 consecutive earnings misses -- execution concerns — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 17.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 17, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 56%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 33.0% shows genuine earnings power backing the valuation
− Price-to-book of 8.8x prices in significant intangible value
Growth Analyst bullish
69 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 25.8% YoY -- genuine top-line momentum
− 2 consecutive earnings misses -- execution concerns
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 17.8% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 9 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 56.7 to 56.7.

Comparing 2026-09-16 to 2026-09-17 (1 day apart).

Technical Analysis

RSI (14)
53.9
Neutral
MACD Histogram
-0.749
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$68.13
Resistance
$120.62
Bollinger %B
0.45
Inside Bands
Price vs Moving Averages
EMA 9
$86.46 Above
EMA 21
$86.57 Above
EMA 50
$84.32 Above
EMA 200
$94.56 Below

Fundamental Analysis

Valuation
71
Growth
74
Profitability
99
Financial Health
71
Cash Flow
70
Valuation
P/E Ratio 19.9×
P/B Ratio 5.88×
PEG Ratio 0.18
Dividend Yield 0.00%
52W High $156.00
52W Low $60.10
Quality & Growth
ROE 4022.2%
ROA 1781.1%
Gross Margin 5869.4%
Operating Margin 1220.8%
Revenue Growth YoY
Debt / Equity 1.68
AI Fundamental Assessment
P/E ratio of 19.9 (inexpensive relative to a 15-40x range); Price-to-book of 5.9x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 40.2%; Return on assets of 17.8%; Net margin of 22.7%; Gross margin of 58.7%; Current ratio of 6.62 (healthy short-term liquidity); Debt-to-equity of 1.67; Free cash flow per share is positive (2.29); Most recent quarter missed estimates by 8.9%; 2 consecutive earnings misses; EPS growth accelerating (-43.4% -> +46.7% QoQ); Analyst estimates rising over recent quarters
Get the Full TMDX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime